VLP stabilized vaccine compositions
The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.
1. A liquid composition comprising virus-like particles (VLPs), an immunogenic component and a stabilizing agent comprised of one or more gelatins degraded to an average molecular weight of about twenty kilodaltons or less, wherein the immunogenic component is a Staphylococcal polysaccharide antigen, wherein the composition is maintained as a liquid and as a liquid stored at ambient temperatures without significant loss of immunogenic activity, and wherein the composition has not been maintained in a non-liquid state.
2. The composition of claim 1 , wherein the VLPs are obtained from the structural components of a virus.
3. The composition of claim 2 , wherein the virus is hepatitis virus or human papilloma virus.
4. The composition of claim 1 , further comprising one or more amino acids, or one or more sugar alcohols, or any combination thereof.
5. The composition of claim 1 , wherein the one or more gelatins are degraded chemically or mechanically.
6. The composition of claim 5 , wherein the one or more degraded gelatins are degraded to an average molecular weight of ten kilodaltons or less.
7. The composition of claim 5 , wherein the one or more degraded gelatins are degraded to an average molecular weight of eight kilodaltons or less.
8. The composition of claim 4 , wherein the one or more sugar alcohols comprises sorbitol.
9. The composition of claim 1 , which does not contain an aluminum compound.
10. The composition of claim 1 , wherein the VLP comprises the structural components of hepatitis virus and the composition does not contain an aluminum compound.
11. The composition of claim 1 , which further contains a pharmaceutically acceptable carrier selected from the group consisting of alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, mineral oils, liquid petrolatum, isopropylpalmitate, polyethylene ethanol, polyoxyethylene monolauriater, sodium lauryl sulfate, an anti-oxidant, a humectant, a viscosity stabilizer or modifier, a colorant or a flavoring agent.
12. The composition of claim 1 , which remains immunogenic at temperatures from 4° C. to 50° C.
13. The composition of claim 1 , which remains immunogenic through freezing and thawing.
14. The composition of claim 1 , which is a vaccine.
15. A liquid composition comprising one or more structural components that form virus-like particles (VLPs) and an immunogenic component, wherein the composition comprises a degraded gelatin with an average molecular weight of from about twenty kilodaltons to about 5 kilodaltons, the one or more structural components are obtained from a virus, and the immunogenic component is a viral antigen selected from the group of viruses consisting of enterovirus, hepatitis virus, human immunodeficiency virus (HIV), human papilloma virus (HPV), influenza virus, pertussis virus, rubella virus, tetanus, varicella virus (VZV), flavivirus, West Nile virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, and Zika virus, wherein the composition is maintained as a liquid and as a liquid stored at ambient temperatures without significant loss of immunogenic activity, and wherein the composition has not been maintained in a non-liquid state.
16. The composition of claim 15 , wherein the VLPs are obtained from hepatitis virus or human papilloma virus.
17. The composition of claim 15 , wherein the immunogenic agent comprises a peptide, a protein, a lipid, a fatty acid, a polysaccharide, or a lipopolysaccharide.
18. The composition of claim 15 , which does not contain an aluminum compound.
19. The composition of claim 15 , wherein the degraded gelatin has an average molecular weight of ten kilodaltons or less.
20. The composition of claim 15 , wherein the degraded gelatin has an average molecular weight of eight kilodaltons or less.
21. The composition of claim 15 , which is a vaccine.
22. A liquid composition comprising one or more structural components obtained or derived from hepatitis virus or human papilloma virus that form virus-like particles (VLPs) and an immunogenic component and a stabilizing agent, wherein the stabilizing agent is a degraded gelatin with an average molecular weight of twenty kilodaltons or less, and does not contain an aluminum compound, wherein the immunogenic component is a Streptococcal polysaccharide antigen and the composition is stored at ambient temperatures as a liquid without significant loss of immunogenic activity, and wherein the composition has not been maintained in a non-liquid state.
23. The composition of claim 22 , which is a vaccine.
24. The composition of claim 1 , wherein storage is for at least 6 months.
25. The composition of claim 15 , wherein storage is for at least 6 months.
26. The composition of claim 22 , wherein storage is for at least 6 months.
27. The composition of claim 1 , wherein there is no loss of immunogenic activity after storage for four months.
28. The composition of claim 15 , wherein there is no loss of immunogenic activity after storage for four months.
29. The composition of claim 22 , wherein there is no loss of immunogenic activity after storage for four months.
30. The composition of claim 1 , which, upon administration to a patient, does not generate a general inflammation response or local inflammation at the site of administration.
31. The composition of claim 15 , which, upon administration to a patient, does not generate a general inflammation response or local inflammation at the site of administration.
32. The composition of claim 22 , which, upon administration to a patient, does not generate a general inflammation response or local inflammation at the site of administration.